With our GPCR collection of 550 non-sensory GPCRs (300 human receptors and 250 mouse receptors) in native sequences, we provide functional assay for them in a single format, regardless of the subtypes of Gα proteins coupled. Click below for details or contact us for information about GPCRs of other animal species such as rats, rabbits, dogs, and macaque monkeys.
Filters Sort results
Reset Apply
Species | Receptor | Family | Assays | |
|---|---|---|---|---|
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: histamine EC50: 240 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ à la carte |  Reference agonist: histamine EC50: 190 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Gastrointestinal ⋅ Dermatology ⋅ à la carte |  Reference agonist: histamine EC50: 51 nM | ||
Human | Assay modes: - Panels: - | Reference agonist: EC50: | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ Dermatology ⋅ à la carte |  Reference agonist: nicotinic acid EC50: 5.8 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Dermatology ⋅ à la carte |  Reference agonist: 3‐OH‐octanoic acid EC50: 130 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: kisspeptin‐10 EC50: 1.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: LTB4 EC50: 84 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: LTB4 EC50: 36 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Respiratory ⋅ à la carte |  Reference agonist: LTD4 EC50: 7.9 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Ophthalmology ⋅ Respiratory ⋅ à la carte |  Reference agonist: LTD4 EC50: 400 pM | ||
Human | Assay modes: - Panels: - | Reference agonist: EC50: | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CH3‐carbamyl PAF C‐16 EC50: 840 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: LPA EC50: 400 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: - |  Reference agonist: LPA EC50: 1.7 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: LPA EC50: 1.3 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: LPA EC50: 2.1 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: LPA EC50: 3.0 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ Dermatology ⋅ à la carte |  Reference agonist: LPA EC50: 750 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Hematology ⋅ à la carte |  Reference agonist: S1P EC50: 120 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: S1P EC50: 96 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: S1P EC50: 48 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: S1P EC50: 210 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: MCH EC50: 37 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: MCH EC50: 2.1 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: α‐MSH EC50: 850 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Endocrinology/Metabolism ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: ACTH EC50: 4.1 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: α‐MSH EC50: 180 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: α‐MSH EC50: 600 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: α‐MSH EC50: 8.5 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: melatonin EC50: 100 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: melatonin EC50: 95 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Neurology ⋅ Ophthalmology ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 6.4 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 6.4 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 34 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: - |  Reference agonist: L‐glutamic acid EC50: 5.9 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 190 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 26 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: motilin EC50: 590 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NMU‐23 EC50: 1.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NMU‐23 EC50: 390 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPFF EC50: 22 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPFF EC50: 280 pM | ||
Human | Assay modes: - Panels: - | Reference agonist: EC50: | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPW‐30 EC50: 20 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPW‐30 EC50: 14 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: NPY EC50: 840 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: NPY EC50: 4.6 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPY EC50: 29 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: NPY EC50: 7.6 nM |
Contact Us
Send us a message via the form below or write to us at [email protected].
Ordering Process
Service flow chart
Request a quotation
We hear about the study outline and propose experiments. A non-disclosure agreement is optional.
STEP
1
Place an order
You place an order, ship your compounds to our lab, and pay the fee via bank transfer or by credit card.
STEP
2
Wait
The turnaround time can be as short as two weeks, depending on the study scale and design and the backlog of orders.
STEP
3
Receive the report
You receive the study report in PDF.
STEP
4
